Advertisement CFFT, Pfizer expand cystic fibrosis drug discovery alliance - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

CFFT, Pfizer expand cystic fibrosis drug discovery alliance

Cystic Fibrosis Foundation Therapeutics (CFFT), Pfizer have expanded their drug discovery alliance to develop therapeutics against Delta F508, a common CF mutation.

According to the pre-clinical research alliance, CFFT will spend $58m to advance the drug candidates into clinical trials by the end of agreement period of six years.

CF Foundation president and CEO Robert Beall said, "We are excited to expand our efforts with Pfizer to accelerate the development of more therapies that treat the root cause of CF and benefit the greatest number of people with the disease."

Delta F508 is a specific mutation within the gene for a protein called the cystic fibrosis transmembrane conductance regulator (CFTR).

The primary goal of the alliance is to develop drugs that repair the defective CFTR protein and regain its usual function.

Pfizer BioTherapeutics R&D senior vice president Jose-Carlos Gutierrez-Ramos said, "Innovative collaborations between industry and patient organizations are increasingly critical in expediting the translation of science into new treatments."